Loading...

FOP: Diagnosis, Management, and Therapeutic Horizons

Saturday, September 28, 2024

Luncheon CME Satellite Symposium at the ASBMR, Metro Toronto Convention Center

255 Front Street West

Toronto, Ontario, Canada

Fibrodysplasia ossificans progressiva (FOP) is a progressive and permanently disabling disorder of extraskeletal ossification characterized by episodic and painful flare-ups and irreversible heterotopic ossification in muscles, tendons, and ligaments. Given the heterogeneity of disease presentation, FOP may be misdiagnosed as cancer or fibrosis, leading physicians to order biopsies which can exacerbate the growth of the FOP bone. Malformed toes or thumbs help distinguish this rare disorder from other skeletal problems. With a prevalence of approximately 1.3 individuals per million lives, increasing clinician awareness of signs and symptoms for an early diagnosis is key to helping control clinical manifestations.

In this live CME-accredited presentation, two FOP experts and prominent research leaders will discuss strategies for improving early detection of FOP by recognizing clinical signs and symptoms, review the genetics and causes associated with the disease, and provide the latest clinical trial data describing potential treatments for the prevention of heterotopic ossification (HO) in patients with FOP.

You must be registered for the ASBMR annual meeting to attend this presentation. 

Schedule

* Times are EST
12:35 PM Registration and Luncheon
12:45 PM Welcome, Disclosures, Supporter Acknowledgement
12:50 PM Clinical Presentation: Signs, Symptoms, Genetics

Triggers of Episodic Events
Management Medication, Rehabilitation, and Trauma Avoidance
Current and Emerging Treatment Options

01:35 PM Audience Q&A
01:45 PM Adjourn

Presenters

Matthew Drake, MD, PhD

Associate Professor of Medicine
Division of Endocrinology, Diabetes, Metabolism and Nutrition
Department of Internal Medicine
Mayo Clinic
Rochester, MN, USA

Angela M. Cheung, MD, PhD, FRCPC

Professor of Medicine
KY and Betty Ho Chair in Integrative Medicine
University of Toronto Division of General Internal Medicine and Endocrinology
Department of Medicine and Joint Department of Medical Imaging
University Health Network and Sinai Health System
Senior Scientist
Toronto General Hospital Research Institute and Schroeder Arthritis Institute
Tier 1 Canada Research Chair in Postmenopausal and Musculoskeletal Health
Toronto, ON, Canada

Accreditation

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Canadian CME: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

The UEMS-EACCME®: The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Nursing CEUs: This activity is designated for 1 contact hour.  Note:  The American Academy of Nurse Practitioners (AANP) accepts certificates of participation as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements

Educational Objectives

At the conclusion of this conference, you should be able to:
  • Recognize the signs and symptoms of FOP to prompt a timely diagnosis
  • List potential misdiagnoses, or diagnosis by exclusion, when applying genetic testing, clinical evidence, and imaging diagnostic strategies to differentiate FOP from other disorders
  • Identify strategies to reduce the risk of episodic events/flare-ups during routine clinical care visits
  • Employ a management plan that includes medication, trauma avoidance, and supportive care principles
  • Describe efficacy and safety profiles of current and emerging FOP-specific therapies that have the potential of reducing new abnormal bone formation

Supporter

IPSEN BIOPHARMACEUTICALS